<DOC>
	<DOCNO>NCT01884415</DOCNO>
	<brief_summary>The objective clinical trial compare response rate obtain two different vaccination scheme HBV cirrhotic patient . These patient must candidate liver transplantation , fail seroconversion ( anti-HBs &lt; 10 IU/ml ) three intramuscular dos 40 µg .</brief_summary>
	<brief_title>Phase III , Study Evaluate Efficacy Two Different HBV Vaccination Schemes Patients With Hepatic Cirrhosis</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Cirrhotic patient , potential candidate liver transplantation , indication HBV vaccination ( HBsAg negative antiHBs negative ) . 2 . Patients treatment HBVAXPRO® show response first cycle vaccination three intramuscular dos 40 µg 0 , 1 2 month . 3 . Patients 18 year old . 4 . Negative pregnancy test . 5 . Patients give consent participate study . 1 . Absolute contraindication HBV vaccine . 2 . Medical history allergy component vaccine . 3 . Chronic renal failure hemodialysis . 4 . Presence antibody Human Immunodeficiency Virus . 5 . Patients seroconversion ( antiHBs &gt; 10 IU /ml ) first three dos vaccine . 6 . Lack consent participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>